SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy

@article{Kaminski2008SV2API,
  title={SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy},
  author={R. Kaminski and A. Matagne and K. Leclercq and M. Gillard and P. Michel and B. Kenda and P. Talaga and H. Klitgaard},
  journal={Neuropharmacology},
  year={2008},
  volume={54},
  pages={715-720}
}
SV2A, a synaptic vesicle protein, has been recently identified as a binding target for levetiracetam (Keppra). The specific mechanism by which SV2A binding leads to seizure protection has not yet been fully elucidated. However, a functional correlation between SV2A binding affinity and anticonvulsant potency has been observed in the mouse audiogenic seizure model. The present study was undertaken to test whether similar correlations exist in rodent models of partial and generalized epilepsies… Expand
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
TLDR
Emerging data indicate that there may be important roles for two other SV2 isoforms (SV2B and SV2C) in the pathogenesis of epilepsy, as well as other neurodegenerative diseases, suggesting potential novel therapies for levetiracetam and its congeners. Expand
Interaction of Approved Drugs with Synaptic Vesicle Protein 2A
TLDR
Loratadine and quinine represent new lead structures for anti‐epileptic drug development and are revealed to be the most potent SV2A protein ligands of the investigated drug library. Expand
Antiepileptic effects of levetiracetam in a rodent neonatal seizure model
TLDR
LEV suppressed acute seizures induced by perinatal hypoxia and diminished later-life seizure susceptibility and seizure-induced neuronal injury, providing evidence for disease modification. Expand
Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor
TLDR
Padsevonil is a first-in-class AED candidate with a unique target profile allowing for presynaptic and postsynaptic activity and displayed nanomolar affinity for the three synaptic vesicle 2 protein isoforms and micromolar affinityFor the benzodiazepine binding site on GABAA receptors. Expand
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
TLDR
In amygdala-kindled rats, seletracetam increased the generalized seizure threshold current and decreased the duration of the after-discharge and the seizure severity observed at the after -discharge threshold current, and generally had a much more potent effect than previously observed for levetiracetam. Expand
SV2A in Epilepsy: The Plot Thickens
TLDR
Findings that reduced expression of SV2A could contribute to the increased epileptogenicity are supported and whether this affects the effectiveness of levetiracetam needs to be further investigated. Expand
SV 2 A IN EPILEPSY : THE PLOT THICKENS Decreased Expression of Synaptic Vesicle Protein 2 A , the Binding Site for Levetiracetam , during Epileptogenesis and Chronic Epilepsy
Decreased Expression of Synaptic Vesicle Protein 2A, the Binding Site for Levetiracetam, during Epileptogenesis and Chronic Epilepsy. van Vliet EA, Aronica E, Redeker S, Boer K, Gorter JA. EpilepsiaExpand
Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
TLDR
Simulation predicted that at therapeutically relevant doses, brivaracetam should occupy more than 80% of SV2A in human brain, in line with levels of occupancy observed in pre-clinical models of epilepsy. Expand
Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited
TLDR
The general mechanism of action of AEDs is reviewed, an updated and critical overview about the experimental findings of LEV's cellular targets (in particular the synaptic vesicular protein SV2A) are given and whether LEV represents a new class of Aed is asked. Expand
Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property
TLDR
Comparison to efficacious doses from the seizure tests support the view that there may be a better separation with the newer AEDs, and somewhat similar effects of phenytoin, valproate, pregabalin and lacosamide on attention and reaction time are highlighted. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes.
TLDR
The presence of specific binding sites for [3H]levetiracetam in rat central nervous system (CNS) and a possible role of this binding site in the anticonvulsant activity of levetir acetam support the singular pharmacological profile of this compound. Expand
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
  • B. Lynch, N. Lambeng, +4 authors B. Fuks
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2004
TLDR
The experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2 a, supporting previous indications that LEv possesses a mechanism of action distinct from that of other antiepileptic drugs. Expand
Activity profile of pregabalin in rodent models of epilepsy and ataxia
TLDR
The findings suggest that pregabalin has an anticonvulsant mechanism different from the prototype antiepileptic drugs and similar to that of gabapentin except with increased potency and bioavailability. Expand
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
TLDR
The results suggest that levetiracetam may offer an effective, broad-spectrum treatment of epileptic seizures in patients, with a minimum of adverse effects, as compared with existing antiepileptic drugs. Expand
Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
TLDR
The results with levetiracetam argue for a clinical application in both petit mal, absence epilepsy and in treating generalised tonic-clonic and partial seizures. Expand
Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
TLDR
A unique preclinical profile of levetiracetam is revealed, distinct from that of all known AEDs, suggesting that levetIRacetam could represent the first agent in a new class of AED's, and may possess antiepileptogenic properties. Expand
Felbamate and meprobamate: a comparison of their anticonvulsant properties
TLDR
The unexpectedly high activity of meprobamate justifies a second look at the anticonvulsant properties of the drug, especially since it was extensively used as an anxiolytic drug in the past with few obvious serious side effects. Expand
The Mechanism of Carbamazepine Aggravation of Absence Seizures
TLDR
Data demonstrate that CBZ acts at the VB thalamus to aggravate absence seizures in GAERS and that activation of GABAA receptors is critical to this effect. Expand
Antiepileptic drug discovery: lessons from the past and future challenges
  • H. Klitgaard
  • Medicine
  • Acta neurologica Scandinavica. Supplementum
  • 2005
TLDR
The use of new epilepsy models has led to the discovery of levetiracetam, an AED with a truly unique mechanism of action, devoid of anticonvulsant activity in normal animals, but with potent seizure suppression in genetic and kindled chronic epilepsy models, and an unusually high safety margin. Expand
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A).
TLDR
It is demonstrated that SV2A is an essential protein and implicate it in the control of exocytosis, andalyses of synapse ultrastructure suggest that altered neurotransmission is not caused by changes in synapse density or morphology. Expand
...
1
2
3
4
...